Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $137.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments